Genta Incorporated to Present at the ROTH Capital Partners New York Conference |
(Archive News Story - Products mentioned in this Archive News Story may or may not be available from the manufacturer.)
Gentag, Inc.
3299 K Street, NW, Suite 100
Washington, DC, WA, 20007
USA
Press release date: August 28, 2007
BERKELEY HEIGHTS, N.J., Aug. 28 / -- Genta Incorporated (NASDAQ:GNTA) announced today that the Company's Chairman and Chief Executive Officer, Dr. Raymond P. Warrell, Jr., will provide a company overview at the ROTH Capital Partners New York Conference on Wednesday, September 5th at 5:00 pm EDT. The conference will be held at The Westin New York at Times Square hotel in New York City.
The presentation will be webcast and accessible at the Investor Relations section of the Company's website at: http://www.genta.com/investorrelation/events.html.
The presentation will be archived for 30 days.
About Gentao Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. The Company's research platform is anchored by two major programs that center on oligonucleotides (RNA- and DNA- based medicines) and small molecules. Genasense(R) (oblimersen sodium) Injection is the Company's lead compound from its oligonucleotide program. The leading drug in Genta's small molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer related hypercalcemia that is resistant to hydration. Genta is partnered with IDIS (www.idispharma.com) on a program whereby both Ganite® and Genasense® are available on a "named- patient" basis in countries outside the United States. For more information about Genta, please visit our website at: www.genta.com.
CONTACT: Tara Spiess TS Communications Group, LLC info@genta.com (908) 286-3980
FCMN Contact: Pignio@genta.com
Source: Genta Incorporated
Web site: http://www.genta.com/
|
|
|
|
|
|
|
|
|
|
|
| 
